Tissue inhibitor of metalloproteinases-l (TIMP-l), the major physiological matrix metalloproteinase inhibitor and a potent antimetastatic factor, also stimulates the growth of erythroid progenitors (erythroid-potentiating activity). We analyzed the relationship between the growth factor activity and protease inhibition by preparing purified TIMP-1 "knockout" proteins lacking in vitro antiproteolytic activity. The growth-stimulatory effect of these N-terminal TIMP-1 point mutants, as tested in an in vitro assay using erythroid precursors (erythroid burst-forming units) was equal to that of unmutated TIMP-1. A fully antiproteolytic C-terminal TIMP-M ATRIX METALLOPROTEINASES (MMPs) are a class of proteolytic enzymes responsible for degradation of extracellular matrix (ECM) components and are specifically inhibited by the tissue inhibitors of metalloproteinases (TIMPs),' a class of proteins consisting of at least three secreted inhibitors, TIMP-1 ,? TIMP-2,' and most recently TIMP-3.4-6 MMP inhibition by TIMPs is not precisely understood but involves a high-affinity stoichiometric interaction of TIMP with the metal ion-containing MMP-active site.' Through their interaction with MMPs, TIMPs regulate ECM stability and, therefore, influence normal and pathological processes that involve substantial remodeling of ECM, such as wound-healing,' angiogenesis,',"' inflammation and arthritis,""3 and most notably tumorigenesis and meta~tasis.'~"' Although the TIMPs are primarily considered to be antiproteolytics, an effect on the growth of erythroid cells and, more recently, on several other cultured cell lines has been described. Indeed, TIMP-I was originally identified as a homologue of erythroid-potentiating activity (EPA), a factor isolated from the conditioned medium of a T-lymphoblast cell line. EPA has been shown to stimulate erythroid burstforming units (BFU-E) and erythroid colony-forming units human erythroleukemia cell lines." TIMP-1 was also shown to stimulate in vivo erythropoiesis in mice."," EPA has subsequently been shown for TIMP-2.'4 Furthermore, it is now clear through several recent reports that TIMP-1 and TIMP-2 are mitogenic for nonerythroid cells, including normal kein vitroZ.i8-2U and in as well as the growth of cultured 
1 truncation also stimulated growth in the erythroid burstforming unit assay. The results indicate that the influence of TIMP-1 on erythroid precursor growth is independent of its ability to inhibit metalloproteinases. TIMP-1 is analogous to proteins that have both proteolytic and growth factor activity, such as plasmin, thrombin, and urokinase. However, TIMP-1 is novel in this regard because it is a metalloproteinase inhibitor. We show that the antiproteolytic and growth factor activities of the TIMP-1 molecule are physically and functionally distinct.
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ratinocytes and
Finally, TIMP-2 appears to be capable of inhibiting the growth of basic fibroblastic growth factor (bFGF)-induced human microvascular endothelial cells,'x. *' ) in an effect that is not mimicked by the addition of metalloproteinase antibodies or a synthetic metalloproteinase inhibitor." These observations led Murphy et to conclude that the antiproteolytic and growth effects of TIMP-2 might be independent. Further support for this hypothesis includes the retention of' growth-stimulatory activity of TIMP-2 after its complexation with and proteolytic inactivation of progelatinase A (in which TIMP-2 is sequestered), as well as the fact that growth potentiation by TIMP-2 is maintained after reductive alkylation, which irreversibly abolishes antiproteolytic activity.") Finally, specific binding of TIMP-I and TIMP-2 ligands to the surface of cells sensitive to TIMP growth effects has been identified and could point to a receptor-mediated mechanism for growth potentiation.?5."
The structural relationship of the growth effect to the antiproteolytic function of TIMPs is unknown, because mapping of the former activity has not yet been attempted. However, the antiproteolytic function is sensitive to reduction of highly conserved disulfide residues located throughout the TIMP structure and appears to depend on critical residues located in a 10 amino acid region (residues 3-13) of the extreme Nterminus." Deletion of the C-terminal hinge domain does not appreciably affect protease inhibition.?? It seems unlikely from further studies that a more discrete MMP inhibitory domain
To investigate the interdependence of EPA and MMP inhibition and to begin to define regions of TIMP-I necessary for EPA, we prepared a set of TIMP-I proteins deficient in MMP inhibition and tested these proteins, as well as several synthetic MMP inhibitors, in in vitro colony stimulation assays using BFU-E. Mutation of two N-terminal residues (His7Ala and Gln9Ala) had previously been shown to efficiently disrupt MMP inhibitory activity but not to affect overall structural integrity or binding to MMP." Also, a Cterminal TIMP-I truncation that retained MMP inhibition had been identified.i3 These findings were exploited in the current study to show that EPA and MMP inhibition are structurally distinct activities of TIMP-I .
MATERIALS AND METHODS
Cell culture und cmtibodies. COS-7 were maintained in Dulbec-CO's modified Eagle's medium (DMEM; GIBCO-BRL, Gaithers- burg, MD) and 10% fetal calf serum (FCS; GIBCO) with antibiotics. The monoclonal antibody (MoAb) Myc 1-9E10, raised against a 10 amino acid sequence (EQKLISEEDL) of the human c-myc, was purified from ascites using Gammabind-Sepharose (Pharmacia, Uppsala, Sweden). Purified antihuman EPA MoAb 6B11 was kindly provided by Dr Regina Santella (Columbia Medical College, New York, NY).
Preparation of myc-tagged Constructs. Polymerase chain reaction (PCR) was performed for 35 cycles (1 minute at 94°C. 2.5 minutes at 53°C. and 1.5 minutes at 72°C) with AmpliTaq DNA polymerase (Perkin-Elmer, Norwalk. CT), 100 ng vector DNA and 1 pmol/L primer. Reaction products were analyzed by agarose gel electrophoresis and purified from gels using Prep-a-Gene beads (BioRad, Hercules, CA). For mutations, a human TIMP-I cDNA, cloned into Bluescript I1 KS(+) (Stratagene, La Jolla, CA), was provided by Dr Steven Clark (Genetics Institute, Cambridge, MA). DNA encoding 10 amino acids of the myc-epitope was inserted via PCR at positions corresponding to (1) amino acid 128 for generation of the myc-tagged truncation (AC128) and (2) the C-terminus for the fulllength protein (wild-type [WT]). For myc tag addition, a 66-mer antisense oligonucleotide 5'-gttacggaattctca CAAGTCCTCTTCAGAAATGAGC~GCTCggctatctgggaccgcaggga-3' (Northwestem University Biotechnology Facility, Chicago, IL) containing 21 bases from the 3' TIMP-I cDNA terminus (italics), was used to add the myc sequence (capitalized), a stop codon, and an EcoRl site (underlined) via PCR. The purified reaction product was subcloned into Bluescript with EcoRI. The AC128 construct was generated using a 63-mer antisense primer 5'-ttacgguatrctca CAAGTCCTCT-
TCAGAATAGCTTITGCTCacugccaacugtgtaggt-3'.
Preparation of mutants. Both tagged cDNAs were subcloned into Bluescript, yielding pS2ACI28myc and pS2WTmyc. which were used to generate point mutations. For mutagenesis, reactions used the pS2WTmyc template and mutagenic primers consisting of short sequences spanning each target base, synthesized as follows (sense strand listed, altered codon underlined): His7Ala: 5'-GTGTCCCACCCGCCCCACAGAC-3', Gln9Ala: 5'-CCCCACC-CAGCGACGGCCTTC-3'. His7AlaGln9Ala: 5'-GTCCCACCCGC-CCCAGCGACGGCCTTCTGC-3'. Tyr35His: 5'-GACCACCTTAC ACCAGCGTTATG-3'. Script KS or SK were used as complementary primers. Paired mutant strands were then used with script primers to generate four mutant cDNAs, His7Ala. Gln9Ala, His7A-laGln9Ala and TydSHis, which were sequenced and subcloned into p91023(B), a simian virus 40 (SV40)-dependent mammalian expression vector.
Metabolic labeling and myc-immunoprecipitation. COS-7 were transiently transfected as described. Cells were labeled at 24 hours in cysteine/methionine-free DMEM for 2 hours with 200 pCi
[3SS]methionine/cysteine Trans-label (New England Nuclear, Boston, MA). For immunoprecipitations, media were incubated with MoAb 9EIO for 1 hour at 21°C. were washed 5 times with RlPA buffer (150 mmol/L NaCI, 1 % NP40,0.5% deoxycholate, 0.1% SDS, 50 mmol/L Tris HCI [pH 7.5]), and were analyzed by sodium dodecy1 sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography.
Assay of truncated stromelysin binding. tMMP3 was tagged with NHS-LC-Biotin (Pierce, Rockford, IL) and was checked for loss of activity in the soluble enzyme assay. Complexes of biotinylated tMMP3 and myc-tagged TIMP-I were prepared by incubating increasing quantities of mutant with 1 ng biotinylated t"P3 for 1 hour at 37°C in binding buffer (phosphate-buffered saline [PBS] + 1% bovine serum albumin). Complexes were applied to the wells of enzyme-linked immunosorbent assay (ELISA; Nunc, Naperville, IL) plates that had been coated with 1 pg of a-EPA 681 I MoAb and blocked with binding buffer for 1 hour at 37°C. After 1 hour, wells were washed 3 times with PBS, incubated for 30 minutes with a mixture of biotinylated alkaline phosphatase and avidin (Pierce), developed via the para-Nitrophenylphosphate (PNPP) substrate reaction, and quantitated by spectrophotometry at 405 X. The amount of each mutant TIMP used was calibrated to yield equal reactivity in parallel blank (no tMMP3) reactions that were washed as described, incubated with biotinylated 9E10 amyc MoAb, and developed as above. Specific binding was confirmed by the addition of 1,000-fold excess unlabeled tMMP3 to the binding buffer-containing complexes. No binding of either TIMP mutants or tMMP3 was detected in the absence of coating antibody (data not shown).
Assay of EPA activiry. Human peripheral blood BFU-E were assayed as described.'3 Briefly, 3 X IOs nucleated buffy-coat cells from human peripheral blood were plated in methyl cellulose containing 10% FCS and 0.5 U/mL human erythropoietin in 96-well flat-bottomed microtiter plates containing 100 pL/well. Erythroid bursts containing a minimum of 50 hemoglobinized cells were scored at 7 to 14 days using an inverted microscope. Test samples were diluted in PBS to final concentrations of 50 to 1 0 0 pmoVL. Control samples consisted of PBS buffer without the addition of test material. All additions were made in 10 pL volumes, and control samples typically contained 20 to 25 BFU-Wwell.
RESULTS
Cloning and preparation of constructs. PCR was used to insert DNA encoding 10 amino acids of the human c-myc A set of myc-tagged amino -(N) terminal point mutants (His7Ala, Gln9Ala, His7AlaIGln9Ala and Tyr35His) was then generated via PCR using the WT template ( Fig IB) . Correct mutagenesis was confirmed by DNA sequence analysis and the constructs were cloned into the expression vector p91023(B), which provides for efficient SV40 large T dependent replication and expression in COS-7 cells (Fig IC) . The mutations are superimposed on a linear model of TIMP-I structure based on disulfide bonding patterns (Fig 2) . The Expression and secretion of protein in COS-7-conditioned media. Duplicate cultures from (A) were metabolically labeled for 2 hours with [35Slmethionine/cysteine. Secreted media were trichloroacetate-precipitated t o determine incorporation of label, and equal aliquots of incorporated cpm were analyzed on a 15% SDS-PAGE gel by autoradiography. (C) Immunoprecipitation of 3SS-labeled myc-tagged proteins from COS-7-conditioned media prepared in (6) and concentrated 50-fold. Media were incubated with 25 pg/mL purified a-myc MoAb 9E10, and immune complexes were isolated on Gammabind Plus-Sepharose and were analyzed by SDS-PAGE as in (B). Numbers below the figure refer t o the relative amount of labeled conditioned medium in the immunoprecipitation. For Northern blotting, RNA was isolated from transiently transfected COS-7 using guanidinium isothiocyanatelCsCl centrifugation. Total RNA (10 mg) was electrophoresed and blotted t o Hybond nylon membranes (Amersham, Arlington Heights, IL). Membranes were probed with a human TIMP-1 cDNA probe, washed, and processed for autoradiography.
location of the N-terminal mutations within a short stretch (amino acids 3-13) of sequence shared by loops I and 3 of TIMP-I is shown. Numbers refer to the amino acid position relative to the signal peptide cleavage site (cysteine residue at position 1). then transiently transfected into COS-7 cells. To verify adequate transcription, total RNA was collected 24 hours posttransfection and analyzed by Northern blot using a human TIMP-I cDNA probe (Fig 3A) . The clones were found to express relatively equal amounts of TIMP-I mRNA. To confirm that this high level transcription was reflected by an increase in secreted protein, duplicate transfections were metabolically labeled with ['SS]methionine/cysteine, and the secreted media were analyzed by SDS-PAGE and autoradiography (Fig 3B) . The WT, ACl28, and Tyr35His mutants were efficiently secreted, constituting the major band of labeled protein, but the His7Ala, Gln9Ala, and His7Ala Gln9Ala mutants were not detectable. To confirm that immunoreactive protein was being produced in these clones, concentrated conditioned medium derived from these three transfections was immunoprecipitated with MoAb 9EI0, directed against the myc-epitope tag (Fig 3C) . The analysis shows that His7Ala and Gln9Ala, as well as the double mutant (not shown), are expressed at approximately I % of the WT level, because 100-fold equivalents of conditioned medium from these clones were required to immunoprecipitate specific bands of approximately equal intensity to those in the WT lane.
PuriJication of mutant proteins. Having verified the synthesis and secretion of myc-tagged protein in the transfections, purification from secreted media was accomplished using a two step procedure combining myc-epitope immunochromatography with fast-protein liquid chromatography (FPLC) size fractionation. For the abundantly expressed WT and AC128 proteins, IO-fold concentrates of 200-mL batches of medium were applied to an MoAb 9E10 a-myc immunoaffinity column. Figure 4A shows the column profile for loading and elution of the WT protein. The eluant ( Fig  4A, peak I ) obtained on treatment of column-bound protein with 100 mmol/L glycine pH 2.5 was analyzed by silverstained SDS-PAGE and was shown to consist of a major 3 1 -kD band and a minor 45-kD band (Fig 4A, silver-stained SDS-PAGE profile shown within peak 1). Peak I was concentrated, applied to an FPLC gel filtration column, and resolved into two further peaks, ie, peak 2, containing the 45-kD band, and peak 3, containing a single 31-kD band (Fig 4B, silver-stained profile within the peak). Peak 3 was immunoreactive on Western blots using MoAb 9E10 a-myc 
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( Fig 4C, right panel) . Figure 4C summarizes the silver-staining profile (left panel) and 9E10 a-myc immunoblotting pattern (right panel) of duplicate samples from each purification fraction. Typical purification yields for the WT and His7Ala proteins are summarized in Table I 
Bio-Rad dye binding assay.
medium, whereas 20 to 30 pg of His7Ala was obtained from 2 to 3 L of medium. To increase yields of the three Nterminal point mutations in subsequent purifications, an additional immunoaffinity chromatography step was added. An initial 6BI I antihuman TIMP-I MoAb column was used to enrich specific protein before application to the 9EIO column, which somewhat improved TIMP-I protein yields. Qucrlittrtiw trsscry of ~cl~rtir?~rsc~ inhihition. Gelatin inhibitor zymography was used to confirm that the purified proteins had retained the ability to inhibit MMP, and to provide a general estimate of gelatinase inhibition. Figure S shows a 9E10 a-myc immunoblot (upper panel). confirming equal loading of purified. ruy-tagged TIMP-I mutants by immunoreactivity. A duplicate gelatin inhibitor zymogram (Fig S,  lower panel) indicates that WT. ACl28, and Tyr3SHis show equal levels of inhibition but that His7Ala fails to show inhibition in this assay (as well as Gln9Ala and His7A-laGln9Ala; data not shown). In the assay, gelatin and a mixture of proteases derived from rabbit epithelial explant cultures, are copolymerized into the running gel of a IS% SDS-PAGE gel (see Materials and Methods). After Coomassie Blue staining, inhibitory activity is visualized as darkly stained areas on a lighter background. Controls confirmed that these areas did not correspond to stained protein bands but to actual gelatinase activity (not shown). Additionally, myc-tagged WT protein, a recombinant bacterially purified TIMP-I (kindly provided by Dr. David Carmichael, Synergen. Inc, Boulder. CO), or untagged TIMP-I show the same level of activity in the assay (data not shown).
Querntitcrthv crsscry of MMP3 irlhihition. The ability of each purified n?y-tagged TIMP-I protein to inhibit an MMP target was analyzed using a soluble radiolabeled substrate cleavage assay.7" In this assay, proteinase activity is detected by release of radioactivity from a ['H] carboxymethylated transferrin substrate. As shown in Fig 6. WT. ACI28, and Tyr35His show indistinguishable inhibition curves for tMMP3, a truncated stromelysin enzyme (kindly supplied by Dr Alice Marcy, Merck Research Laboratories. Rahway, CHESLER ET AL NJ). WT TIMP-I showed complete inhibition at an inhibitor:enzyme molar ratio of 3: I with a 50% inhibition concentration (IC5,,) of approximately I .S: I (Fig 6, 0 ) . Partial inhibition by His7Ala. GlnBAla. and the double mutant was detected in this assay only at greater than 7:l molar ratios of inhibitor:enzyme (Fig 6. W. U. and A) . The results divide the TIMP-I proteins into two groups. those that retain MMP inhibition (WT. ACl28, and Tyr3SHis) and those that have effectively lost the capacity to inhibit MMP (His7Ala. Gln9Ala and the double mutation). The activities of the various tested proteins are summarized in Table 2 .
Ri~~elin,q of TIMP-I 111r4ter1rt.s to MMP3. The ability of each purified TIMP-I mutant to bind to tMMP3 was assayed via ELISA. using a biotinylated tMMP3 target protease (btMMP3). In this assay, TIMP-IhtMMP3 complexes were preformed for I hour in binding buffer and then applied to ELISA plates coated with MoAb 691 I a-EPA (a human TlMP protein MoAb). After binding to the immobilized antibody, residual protein was removed by washing. Immobilized. TIMP-bound btMMP3 was quantitated by incubation with a preformed mixture of avidin and biotinylated alkaline Blocked membranes were incubated for 1 hour with 25 mglmL MoAb 9E10 in blocking buffer, washed 4 times in PBS, and incubated for 1 hour with 1 mglmL horseradish peroxidase-linked goat antimouse antibody (KirkegaardlPerry Laboratories). Blots were rewashed as above and developed using ECL-chemiluminescence (Amersham) onto Hyperfilm-ECL as directed by the manufacturer. For zymography, SDS-PAGE was performed as above except that the running gels contained copolymerized 0.1% gelatin (DIFCO, Detroit, MI) and a mixture of proteinases expressed from rabbit epithelium, in a modification of a previously described protocol. ' For personal use only. on November 11, 2017 . by guest www.bloodjournal.org phosphatase and spectrophotometric detection at 405 nm (Fig 7, solid lines) . Specificity of complex formation was confirmed by competing parallel reactions with a 1,000-fold excess of unbiotinylated t"P3, which reduced binding to background levels (Fig 7, dotted lines) . Figure 7 shows that the ability of the TIMP-1 point mutants to bind t"P3 is equal to that of either the WT or A128 proteins.
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EPA activity of TIMP-I mutants and synthetic inhibitors. The mitogenic potential of COS-7 TIMP-1 expressing conditioned media and purified myc-tagged proteins was measured as the ability to stimulate BFU-E colony formation in microwell assays. This EPA typically stimulates a twofold to threefold maximal increase in the number of erythroid colonies per well and generally increases individual colony size. Data in this assay are presented as potentiation above background, the number of colonies observed using equivalent amounts of mock-transfected COS-7 conditioned medium. These values did not differ significantly from those of control buffertreated microwells. Media containing untagged WT protein shows this activity (Fig 8A, 0) , and media containing myctagged WT protein shows a similar profile (Fig 8A, 0 ) . Purified, myc-tagged proteins were tested in the same assay (Fig 8B) and again showed EPA profiles similar to those shown in the assay of conditioned media. Therefore, myctagging does not appear to influence the EPA of these proteins. It is significant that the EPA profiles obtained for both WT and mutated TIMP-1 proteins were approximately equal. In some cases, EPA is observed over a slightly wider dose range. Generally, however, the magnitude and concentration range of the EPA effect observed here are consistent with previous descriptions of this activity. It is also of interest to note that the purified proteins show EPA in the picomolar concentration range, well below the nanomolar affinity constants reported for TIMP-1 MMP complex formation. Finally, an attempt was made to assess the effects of direct manipulation of protease activity on EPA in the in vitro BFU-E assay. For this purpose synthetic, hydroxamate-based MMP inhibitors (kindly provided by Dr Jamie Conway, Glaxo) were used. These small compounds exert potent inhibition by a direct interaction within the MMP active site. One of these inhibitors, GI213, is identical to BB94, a synthetic inhibitor that has shown some promise in clinical testing as an inhibitor of ovarian carcinoma metastasis. Although all of these inhibitors showed potent inhibition in the soluble Fdd TIMP-1 dilution substrate cleavage assay (described above), none of the inhibitors elicited any EPA when tested over a wide dose range (1 pmoVL to 10 mmol/L) in this assay (data not shown).
DISCUSSION
A system for the generation and rapid purification of TIMP-1 WT and mutant proteins from mammalian cells was established and used to analyze the interdependence of the two major activities of TIMP-1, MMP inhibition and EPA. TIMP-I point mutants lacking MMP-inhibitory activity were assayed for the ability to bind to a protease target and to stimulate erythroid colony formation in EPA assays ( Table  2 ). The N-terminal point mutations of TIMP-1 at His7, Gln9, and a double His7/Gln9 were found to (1) lose MMP inhibitory capacity, ( 2 ) maintain the ability to complex with activated MMP, and (3) fully retain EPA. A C-terminal truncation was indistinguishable from WT TIMP-l in the same assays. Finally, two high-affinity, synthetic MMP inhibitors were found not to show EPA over a wide range of test doses. The EPA profile reported here for TIMP-1 is consistent with previous analyses that showed an approximately twofold to threefold stimulation of erythroid colony formation over a narrow, picomolar dose range20*'1.24.31 and serves as further confirmation of this activity for TIMP-1 protein.
That TIMPs possess growth factor-like activity is remarkable, because they are primarily considered to be tumor suppressors. TIMPs are thought to prevent growth of the primary tumor mass 37 and metastatic foci by inhibiting tumor-induced angiogenesis, as surmised from the strongly inhibitory effects of purified TIMPs in in vitro assays of bFGF-induced endothelial cell migration (Boyden chamber assays), rat corneal neovascularization, and chick chorioallantoic membrane a s~a y s .~. '~.~~ TIMPs may also inhibit tumor cell metastasis and basement membrane invasion by direct binding and inac- Several other molecules, such as thrombin, plasmin, plasminogen activators, trypsin inhibitor and hepsin (reviewed in Scott4') show effects on both proteolysis and cell growth. These bifunctional proteins have pleiotropic roles in the regulation of the clotting cascade, proenzyme activation, and cell growth13 and are primarily serine proteinases or their inhibitors." In each case, a varying dependence of mitogenesis on proteolytic capacity and a variable degree of domainal separation of the two functions is shown. Urokinase, for example, contains a serine protease domain and a separate growth factor (EGF-like) domain, the "GFD" that appears to function mitogenically, independent of proteolysis, through cell surface binding.43 With thrombin, which has a serine-protease domain but no distinct growth factor-like domain, protease-dependent mitogenesis is effected ( l ) by release of bFGF from proteolyzed matrix" and ( 2 ) by binding to and proteolysis of specific cell surface thrombin recept o r~.~~ However, thrombin also elicits protease-independent growth stimulation, mediated by a structurally distinct "loop B" domain. 45 Finally, hepatocyte growth factorkatter factor and macrophage-stimulating protein,46 which are mitogenic for endotheliaVepithelia1 cells and macrophages, respectively, both contain a nonproteolytic serine-protease-like domain that apparently mediates the growth-related effects of these two molecules. Mutation of this domain in hepatocyte growth factor/scatter factor eliminates mitogene~is.4~ Human pancreatic secretory trypsin inhibitor is an example of a mitogenic protease inhibitor that stimulates DNA synthesis and fibroblast growth at doses below the range of its protease interactions, but inhibits growth at doses within this range!' Taken together, the suggestion is of an evolutionary link between proteolysis and mitogenesis that has diverged but is still present to varying degrees in the cited examples?2 It is clear that TIMP-1 is another member of this group of bifunctional proteins, although it is uniquely the first metalloproteinase inhibitor represented. TIMP-1 also does not seem to possess discrete, segregated domains devoted to either of its activities, although this may still reflect a lack of knowledge about TIMP structure. Solution of TIMP crystal structures is ongoing and will be required to support further contentions about TIMP structure/function relationship^!^.^'
The current study supports the concept that the growthrelated activity of TIMP-1 is independent of its ability to inhibit metalloproteinases. Previously, this activity has been proposed to indirectly result from the effects of matrix proteolysis on the release of either growth-regulating matrix subfragments or matrix-sequestered growth factors. This explanation has been satisfying in that it accounts for discrepancies in reports of the stimulatory versus inhibitory effects of TIMP-1 on the proliferation of various cell types?'.
However, several lines of evidence support the notion that EPA and MMP are functionally discrete, such as the specific binding of TIMPs to cell ~urfaces,3'~'~ the persistence of growth stimulation after reductiodalkylation (which eliminates protease inhibition3'), and the evidence obtained here, primarily that (1) TIMP-1 mutants structurally altered to lose MMP inhibitory activity retain EPA and (2) that synthetic MMP inhibitors including BB94 do not elicit EPA, indicating that alteration of MMP activity through active site interaction does not affect the EPA response. Finally, the picomolar concentration range observed for the EPA response is significantly lower than that reported for the affinities of TIMPMMP interactions. ' This last point highlights a difference in reports of the dose ranges evoking growth-related responses with erythroid cells as opposed to other cell types. Nonerythroid cell stimulation has typically been reported to occur in the nanomolar range, although inhibition of cell growth by TIMP-2 (not TIMP-1) also occurs at this l e~e l .~~~' '~*~~"
This heterogeneity may describe a biphasic, dose-sensitive response similar to that of human pancreatic secretory trypsin inhibitor. Alternatively, it may resemble other growth factor-like responses that show highly variable stimulatory versus inhibitory effects depending on the assay system used, the supporting matrix environment, or the target cell type, as is the case with factors such as transforming growth factor p (TGFP).
However, for TIMP-l, a positive response in the EPA assay correlates well with the in vivo erythroid potentiation elicited by this protein on peripheral injection into the bloodstream of anemic mice, in which a strong stimulation of circulating levels of BFU-E and reticulocytes is observed?'.'' The significance of the growth stimulatiodinhibition of nonerythroid cell types is not yet clear.
These preliminary attempts to map EPA to the TIMP-1 structure show that the growth-related and antiproteolytic activities of TIMP-1 are functionally distinct and, perhaps, structurally distinct as well. The implication here is that EPA is localized within the TIMP-1 N-terminus, although more specific mapping will be required to confirm this idea and to locate residues critical to this activity. The identification of N terminal TIMP-1 mutants lacking EPA is a focus of current work and would be particularly useful in our continuing efforts to localize a specific cell surface TIMP-1 receptor and to define a receptor-mediated mechanism for the growthstimulatory effect. For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From
